Home › Funds › Defilade Capital Management, L.P. › ORIC
Defilade Capital Management, L.P. position in ORIC
ORIC PHARMACEUTICALS INC · Health Care
Defilade Capital Management, L.P. reported holding 1,047,690 shares of ORIC (ORIC PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$11.3M, representing 1.52% of its reported portfolio and ranking #26 among its reported holdings. Defilade Capital Management, L.P. has disclosed ORIC holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s ORIC position evolved
Defilade Capital Management, L.P. first disclosed a stake in ORIC in Q1 2026 at 842,928 shares (US$10.7M). The position peaked in Q2 2026 at 1,047,690 shares, worth US$11.3M. Across 2 filings, Defilade Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,047,690 shares valued at US$11.3M — an increase of 204,762 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 842.93K | $10.68M | New |
| Q2 2026 | 1.05M | $11.35M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORIC and 13F data
ORIC (ORIC PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in ORIC — the largest reported positions include Nextech Invest Ltd. (US$77.6M), EcoR1 Capital, LLC (US$72.9M), SR ONE CAPITAL MANAGEMENT, LP (US$50.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORIC
- Nextech Invest Ltd. 7.16M sh · $77.57M · Q2 2026
- EcoR1 Capital, LLC 6.73M sh · $72.87M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.62M sh · $49.98M · Q2 2026
- Venrock Adviser, LLC 4.32M sh · $46.78M · Q2 2026
- NEA Management Company, LLC 4.12M sh · $44.60M · Q2 2026
- AIHC Capital Management Ltd 3.83M sh · $41.46M · Q2 2026
- Column Group LLC 3.54M sh · $38.35M · Q2 2026
- Siren, L.L.C. 3.00M sh · $32.47M · Q2 2026
- First Turn Management, LLC 2.02M sh · $21.85M · Q2 2026
- Integral Health Asset Management, LLC 1.90M sh · $20.58M · Q2 2026
- MPM BioImpact LLC 1.88M sh · $20.38M · Q2 2026
- Vivo Capital, LLC 1.85M sh · $20.02M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held ORIC?
Defilade Capital Management, L.P. has disclosed ORIC holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Defilade Capital Management, L.P.'s current position in ORIC?
As of Q2 2026, Defilade Capital Management, L.P. holds 1.05M shares of ORIC (ORIC PHARMACEUTICALS INC), valued at $11.35M, representing 1.52% of its reported portfolio and ranking #26.
Has Defilade Capital Management, L.P. been buying or selling ORIC?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. increased its position in ORIC. The position peaked in Q2 2026 at 1.05M shares.
Which other funds hold ORIC?
Other major institutional holders of ORIC include Nextech Invest Ltd., EcoR1 Capital, LLC, SR ONE CAPITAL MANAGEMENT, LP, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.